Search results for "plastic"

showing 10 items of 7296 documents

Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas.

2009

A total of 50 neuroblastomas were assessed for frequency of ALK gene copy number aberrations by interphase fluorescence in situ hybridization using a break-apart fluorescence in situ hybridization probe. The data were compared with status of MYCN, 11q, 17q, and 1p36. We observed ALK aberrations (amplification, 1 of 45; gain, 15 of 45 and loss/imbalance, 11 of 45) in a total of 27 (60%) of 45 neuroblastomas. Synchronic MYCN and ALK aberrations accounted for 23 of 45 (51%) tumors; however, MYCN alterations were also detected in 11 (60%) of 18 tumors without ALK aberrations. Our data suggest that copy number aberrations of the ALK gene is a frequent genetic event in the development of neurobla…

medicine.medical_specialtyPathologyGene DosageBiologyPathology and Forensic MedicineNeuroblastomahemic and lymphatic diseasesNeuroblastomamedicineAnaplastic lymphoma kinaseHumansAnaplastic Lymphoma KinaseCopy number aberrationneoplasmsIn Situ Hybridization FluorescenceOncogene ProteinsN-Myc Proto-Oncogene Proteinmedicine.diagnostic_testGenetic AlterationCancerNuclear ProteinsReceptor Protein-Tyrosine KinasesAnatomical pathologyProtein-Tyrosine Kinasesmedicine.diseaseTissue Array AnalysisCancer researchAutonomic neuropathyFluorescence in situ hybridizationHuman pathology
researchProduct

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes

2012

The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncertain and its assessment was the major aim of this study. The different peripheral blood and bone marrow variables required for an adequate morphological classification were blindly evaluated by four cytomorphologists in samples from 50 patients with myelodysplastic syndromes. The degree of agreement among observers was calculated using intraclass correlation coefficient and the generalized kappa statistic for multiple raters. The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, granulocytic and m…

medicine.medical_specialtyPathologyHematologymedicine.diagnostic_testbusiness.industryMyelodysplastic syndromesHematologyErythroid dysplasiamedicine.diseaseGastroenterologyBone marrow examinationmedicine.anatomical_structureInternal medicineRefractory anemia with ring sideroblastsmedicineBone marrowRefractory anemia with excess of blastsbusinessErythroid Precursor Cells
researchProduct

Expression of Cytokeratin 7 and 20 in Pathological Conditions of the Bile Tract

2003

Expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) helps to establish the origin of biliary and metastatic carcinomas. We investigated the expression of CK7 and CK20 in inflammatory, metaplastic and neoplastic conditions of the bile ducts, and evaluated possible relationships between the CK expression pattern and extrahepatic bile duct/gallbladder carcinomas (EBDCs) or intrahepatic bile duct carcinomas (IBDCs). We used immunohistochemistry for the investigation of 48 formalin-fixed, paraffin-embedded specimens grouped as: A) lithiasic or inflamed surgically resected extrahepatic bile ducts/gallbladders: all were CK7+/CK20+; B) percutaneous liver biopsies from patients with chronic …

medicine.medical_specialtyPathologyIntestinal metaplasia2734Intrahepatic bile ductsBile duct tumors; Cytokeratin 20 (CK20); Cytokeratin 7 (CK7); Intestinal metaplasia; Bile Duct Diseases; Bile Duct Neoplasms; Bile Ducts Extrahepatic; Bile Ducts Intrahepatic; Carcinoma; Cell Transformation Neoplastic; Gallbladder Diseases; Gallbladder Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Intermediate Filament Proteins; Keratin-20; Keratin-7; Keratins; 2734Bile Duct DiseasesGallbladder DiseasesKeratin-20Settore MED/08 - Anatomia PatologicaGastroenterologyIntermediate Filament ProteinPathology and Forensic MedicinePrimary sclerosing cholangitisCytokeratinPrimary biliary cirrhosisIntermediate Filament ProteinsBile Ducts ExtrahepaticInternal medicineBile duct tumormedicineHumansCytokeratin 7 (CK7)Bile Duct NeoplasmGallbladder NeoplasmBile ductbusiness.industryGene Expression ProfilingGallbladderKeratin 20CarcinomaGallbladder DiseaseKeratin-7Bile Duct DiseaseCell Biologymedicine.diseaseImmunohistochemistryBile Ducts IntrahepaticCell Transformation Neoplasticmedicine.anatomical_structureBile Duct NeoplasmsKeratinKeratin 7KeratinsGallbladder NeoplasmsbusinessCytokeratin 20 (CK20)HumanPathology - Research and Practice
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

2016

Abstract Background: Management of anemia is a common therapeutic challenge in patients with myelodysplastic syndromes (MDS). Luspatercept (ACE-536), a fusion protein containing modified activin receptor type IIB, is being developed for treatment of anemia in lower-risk MDS. Luspatercept binds GDF11 and other TGF-β superfamily ligands to promote late-stage erythroid differentiation and increase hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014 and Attie K, Am J Hematol, 2014). Aims: This is an ongoing, phase 2, multicenter, open-label study to evaluate the effects of luspatercept in patient (pts) with low-intermediate risk MDS. Endpoints included erythroid response (IWG HI-E), RBC transfus…

medicine.medical_specialtyPediatricsbusiness.industryAnemiaMyelodysplastic syndromesImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyhemic and lymphatic diseasesPharmacodynamicsInternal medicineLuspaterceptCohortmedicineIntermediate riskbusinessLenalidomidemedicine.drugBlood
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

Autonomic nervous control of the urinary bladder

2013

The autonomic nervous system plays an important role in the regulation of the urinary bladder function. Under physiological circumstances, noradrenaline, acting mainly on β(3) -adrenoceptors in the detrusor and on α(1) (A) -adrenoceptors in the bladder outflow tract, promotes urine storage, whereas neuronally released acetylcholine acting mainly on M(3) receptors promotes bladder emptying. Under pathophysiological conditions, however, this system may change in several ways. Firstly, there may be plasticity at the levels of innervation and receptor expression and function. Secondly, non-neuronal acetylcholine synthesis and release from the urothelium may occur during the storage phase, leadi…

medicine.medical_specialtyPhysiologyReceptor expressionUrinary Bladder030232 urology & nephrologyAdrenergicBiologyurologic and male genital diseasesAutonomic Nervous System03 medical and health sciences0302 clinical medicineInternal medicineMuscarinic acetylcholine receptorReceptors Adrenergic betamedicineAnimalsHumansUrotheliumUrinary bladderNeuronal PlasticityUrinary Bladder DiseasesMuscarinic acetylcholine receptor M3Receptors Muscarinicfemale genital diseases and pregnancy complicationsAutonomic nervous systemmedicine.anatomical_structureEndocrinology030217 neurology & neurosurgeryAcetylcholinemedicine.drugActa Physiologica
researchProduct

Doctor, quiero una talla 100

2009

Cuando una paciente consulta al cirujano plástico con la intención de que éste le efectúe una mamoplastia de aumento es, en la mayoría de las ocasiones, difícil interpretar exactamente el volumen que desea. La determinación del volumen de la mama que posee la paciente y del volumen que quisiera tener se ve limitada por inconvenientes técnicos y por la poca precisión en la interpretación psicosocial de las mediciones y cálculos que se pueden hacer. El objetivo de este estudio ha sido desarrollar un sistema que partiendo de las medidas intrínsecas del sujetador permita relacionar el volumen de la mama de la paciente con el volumen de la copa del sujetador que desea y con la prótesis necesaria…

medicine.medical_specialtyPlastic surgeryPrótesis mamariasbusiness.industrymedicineBreast volumeSurgeryskin and connective tissue diseasesbusinessMamoplastia de AumentoBreast augmentationSurgery
researchProduct

Die retrograde Verriegelungsmarknagelung von Humerusschaftfrakturen mit dem unaufgebohrten Humerusnagel

1999

Operationsziel Ubungsstabile Osteosynthese des Humerus mit solidem, intramedullaren Verriegelungsmarknagel in nichtaufgebohrter Technik. Rasche Wiederherstellung von Form und Funktion der betroffenen Gliedmase.

medicine.medical_specialtyPlastic surgerybusiness.industryOrthopedic surgeryMedicineOrthopedics and Sports MedicineSurgeryHand surgeryAnatomybusinessOperative Orthopädie und Traumatologie
researchProduct

Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents

2021

Thrombosis and neoplasms are strictly linked, and the diagnosis of a malignancy is a relevant risk factor for venous thromboembolism (VTE). In particular, between gammopathies, the VTE risk is known to be increased in both monoclonal gammopathy of uncertain significance and in multiple myeloma, with a 3- and 9-fold increase respectively, when compared to the general population. The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. In 2008 the International Myeloma Working Group put out thrombosis prophylaxis recommendations fo…

medicine.medical_specialtyPopulationAntineoplastic Agents030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicinemedicineHumansImmunologic FactorsRisk factoreducationMultiple myelomaLenalidomideeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismGeneral MedicineEvidence-based medicinemedicine.diseaseThrombosisPrevention and controlThalidomideTreatment OutcomeMultiple MyelomabusinessProteasome Inhibitorsmedicine.drugPanminerva Medica
researchProduct